Magnolol has been observed to diminish the phosphorylation of PI3K, Akt, mTOR, p70S6K and 4E-BP1, and this magnolol-induced inactivation of PI3K/Akt/mTOR signaling seems to be cancer type-independent, across a variety of cancer types covering bladder cancer [14], colon cancer [20], gastric cancer [27], glioblastoma [31], lung cancer [37,40], melanoma [43], ovarian cancer [48], prostate cancer [50] and skin cancer [57] (Table 1 and Figure 2). This evidence concerns the gene MTOR and prostate carcinoma.